Randomised clinical trial: a phase 1b study of GB004, an oral HIF‐1α stabiliser, for treatment of ulcerative colitis

BACKGROUND: Epithelial barrier dysfunction contributes to a dysregulated intestinal immune response in ulcerative colitis (UC). GB004 is an orally administered, small molecule, gut‐targeted stabiliser of hypoxia‐inducible factor‐1α, a transcription factor with protective roles at the epithelial laye...

Descripción completa

Detalles Bibliográficos
Autores principales: Danese, Silvio, Levesque, Barrett G., Feagan, Brian G., Jucov, Alina, Bhandari, Bal Raj, Pai, Rish K., Taylor Meadows, Kristen, Kirby, Brian J., Bruey, Jean‐Marie, Olson, Allan, Osterhout, Robin, Van Biene, Courtney, Ford, Julia, Aranda, Richard, Raghupathi, Kartik, Sandborn, William J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Clinical Trial
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305136/
https://www.ncbi.nlm.nih.gov/pubmed/35014040
http://dx.doi.org/10.1111/apt.16753

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9305136/
https://www.ncbi.nlm.nih.gov/pubmed/35014040
http://dx.doi.org/10.1111/apt.16753

Ejemplares similares